Picture of Bio Path Holdings logo

BPTH — Bio Path Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Bio Path Holdings Inc reports results for the quarter ended in June - Earnings Summary

* Bio Path Holdings Inc  BPTH.OQ  reported a quarterly
adjusted
loss of $1.16​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of $-10.60.  The lone analyst forecast for the quarter was for a
loss of $1.54 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Bio Path Holdings Inc's reported EPS for the quarter was a
loss
of $1.16​.
    * The company reported a quarterly loss of $1.87 million.
    * Bio Path Holdings Inc shares had fallen by 24.5% this
quarter and lost 83.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 25.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Bio Path Holdings
Inc is $20.00 
This summary was machine generated from LSEG data August 16 at
01:28 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.54          -1.16          Beat
 Mar. 31 2024      -4.54          -4.88          Missed
 Dec. 31 2023      -5.40          -7.05          Missed
 Sep. 30 2023      -6.80          -6.40          Beat

Recent news on Bio Path Holdings

See all news